KNSA
Kiniksa Pharmaceuticals Ltd
NASDAQ: KNSA · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$58.37
-1.65% today
Updated 2026-06-05
Market cap
$3.99B
P/E ratio
57.02
P/S ratio
5.29x
EPS (TTM)
$0.91
Dividend yield
—
52W range
$26 – $60
Volume
0.7M
WallStSmart proprietary scores
53
out of 100
Grade: C
Hold
Investment rating
10.0
Growth
A+8.5
Quality
A6.5
Profitability
B5.7
Valuation
C+4/9
Piotroski F-Score
Moderate
2.8
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$60.86
+4.27%
12-Month target
$23.74
-59.33%
Intrinsic (DCF)
$197.77
Margin of safety
+77.26%
1 Strong Buy7 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $50.04M — positive
+ Revenue growth 55.50% QoQ
+ 77.26% below intrinsic value
+ Debt/equity 0.01x — low leverage
Risks
- P/E 57.02x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $220.18M | $270.26M | $423.24M | $677.56M | $754.04M | $1.0B |
| Net income | $183.36M | $14.08M | $-43.19M | $59.01M | $22.59M | — |
| EPS | — | — | — | — | $0.91 | $1.28 |
| Free cash flow | $5.70M | $13.17M | $25.41M | $25.41M | $50.04M | — |
| Profit margin | 83.28% | 5.21% | -10.21% | 8.71% | 9.69% | — |
Peer comparison
Smart narrative
Kiniksa Pharmaceuticals Ltd trades at $58.37. representing a P/E of 57.02x trailing earnings. Our Smart Value Score of 53/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 2.77, it sits in the grey zone. TTM revenue stands at $754.04M. with profit margins at 9.69%. Our DCF model estimates intrinsic value at $197.77.
Frequently asked questions
What is Kiniksa Pharmaceuticals Ltd's stock price?
Kiniksa Pharmaceuticals Ltd (KNSA) trades at $58.37, on a P/E of 57.0x and a P/S of 5.3x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Kiniksa Pharmaceuticals Ltd overvalued?
Kiniksa Pharmaceuticals Ltd carries a Smart Value Score of 53/100 (Grade C), which we rate Hold. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $197.77 versus the $58.37 price, a 77.3% margin of safety on a cash flow basis.
What is the price target of Kiniksa Pharmaceuticals Ltd (KNSA)?
The 12-month analyst consensus target is $60.86, about 4.3% above the current $58.37. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of KNSA by 2030?
Our research-backed model puts the 2030 base case at $58.70, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of Kiniksa Pharmaceuticals Ltd (KNSA)?
Our DCF model estimates intrinsic value at $197.77, a +77.3% margin of safety versus today's $58.37. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Kiniksa Pharmaceuticals Ltd's revenue?
Kiniksa Pharmaceuticals Ltd's trailing twelve-month revenue is $754.04M, and our model projects it reaching about $2.16B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Kiniksa Pharmaceuticals Ltd's Altman Z-Score is 2.77, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio5.29x
ROE12.06%
Beta0.12
50D MA$50.72
200D MA$43.58
Shares out0.05B
Float0.04B
Short ratio—
Avg volume0.7M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—